Details of the Drug Combination

General Information of Drug Combination (ID: DCLV6PN)

Drug Combination Name
PSI-938 Sofosbuvir
Indication
Disease Entry Status REF
Hepatitis C, Chronic Phase 1 [1]
Component Drugs PSI-938   DM5ZR4Q Sofosbuvir   DMQI86A
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PSI-938
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 1 [2]
PSI-938 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) TTMVBWH POLG_HCV1 Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Sofosbuvir
Disease Entry ICD 11 Status REF
Hepatitis C 1E51 Approved [3]
Sofosbuvir Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01435044) Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
2 2011 Pipeline of Pharmasset.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
5 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)